Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12425844 | 0.89 | LMNA (0.51) | SMN1; SMN2ALDH1A1USP2HTTNPC1 | |
| SCHEMBL13745751 | 0.89 | HTT (0.55) | SMN1; SMN2ALDH1A1USP2KMT2AMEN1 | |
| SCHEMBL24491632 | 0.87 | HTT (0.41) | NAMPTSMN1; SMN2ALDH1A1HTTLMNA | |
| SCHEMBL24491633 | 0.87 | HTT (0.41) | NAMPTSMN1; SMN2ALDH1A1HTTLMNA | |
| SCHEMBL25512218 | 0.85 | NAMPT (0.45) | NAMPTSMN1; SMN2ALDH1A1HTTLMNA | |
| SCHEMBL25498361 | 0.85 | NAMPT (0.45) | NAMPTSMN1; SMN2ALDH1A1HTTLMNA | |
| SCHEMBL25511897 | 0.85 | NAMPT (0.45) | NAMPTSMN1; SMN2ALDH1A1HTTLMNA | |
| SCHEMBL25074005 | 0.85 | HTT (0.59) | NAMPTSMN1; SMN2ALDH1A1KMT2AHTT | |
| SCHEMBL25074346 | 0.85 | HTT (0.59) | NAMPTSMN1; SMN2ALDH1A1KMT2AHTT | |
| SCHEMBL14471382 | 0.85 | HTT (0.59) | NAMPTSMN1; SMN2ALDH1A1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | NAMPT 1569/4885SMN1; SMN2 4086/4885ALDH1A1 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.